Indication

Essential thrombocytosis

Essential thrombocytosis, more commonly referred to as essential thrombocythemia, is a chronic myeloproliferative neoplasm affecting the hematopoietic system and bone marrow. Read more about Essential thrombocytosis

9 drugs 8 manufacturers

Advertisement

Drugs that treat it

Common Essential thrombocytosis therapies.

Showing 1–9 of 9 drugs

ANAGRELIDE HCL

THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE·+1
TEVA USA

ANAGRELIDE HCL

THROMBOCYTOSIS AGENTS·THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE·+1
TORRENT PHARMAC

ANAGRELIDE HCL

THROMBOCYTOSIS AGENTS·THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE·+1
CHARTWELL RX LL

ANAGRELIDE HCL

THROMBOCYTOSIS AGENTS·THROMBOCYTOSIS IN MYELOPROLIFERATIVE DISEASE·+1
ANI PHARMACEUTI
Filter & compare in the drug finder →Opens the drug finder with Essential thrombocytosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Essential thrombocytosis.

Essential thrombocytosis, more commonly referred to as essential thrombocythemia, is a chronic myeloproliferative neoplasm affecting the hematopoietic system and bone marrow.

It is characterized by the sustained clonal overproduction of mature megakaryocytes leading to elevated circulating platelet counts, typically 450 × 10?/L or greater.

Most cases are driven by acquired somatic mutations that activate the JAK-STAT signaling pathway, predominantly involving the *JAK2*, *CALR*, or *MPL* genes.

While often asymptomatic, affected individuals are at increased risk for arterial or venous thrombosis, microvascular disturbances, bleeding complications, and potential long-term transformation into myelofibrosis or acute leukemia.

Personalize your experience

Follow Essential thrombocytosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it